

Notice of Allowability	Application No.	Applicant(s)	
	10/030,188	LIEBESCHUETZ ET AL.	
	Examiner	Art Unit	
	Sudhaker B. Patel, D.Sc.Tech.	1624	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to 1/16/04.
2. ☒ The allowed claim(s) is/are 1-5, 7-10, 13-14, 21-26, 29, 32-35 and 37.
3. ☐ The drawings filed on _____ are accepted by the Examiner.
4. ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☒ All b) ☐ Some* c) ☐ None of the:
 1. ☒ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
 - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- | | |
|--|--|
| <ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) 2. <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) 3. <input type="checkbox"/> Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date _____ 4. <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit
of Biological Material | <ol style="list-style-type: none"> 5. <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) 6. <input type="checkbox"/> Interview Summary (PTO-413),
Paper No./Mail Date _____ 7. <input type="checkbox"/> Examiner's Amendment/Comment 8. <input checked="" type="checkbox"/> Examiner's Statement of Reasons for Allowance 9. <input type="checkbox"/> Other _____ |
|--|--|

REASONS FOR ALLOWANCE

1. The following is an examiner's statement of reasons for allowance:

2. Applicants' communication paper dated 1/16/04 is acknowledged. Applicants have cancelled claims 6,11,12,15-20,27-28,30-31,36, amended claims 1,2,29,32,34, and added new claim 37. Therefore, the claims under consideration are the claims 1-5,7-10,13-14,21-26,29,32-35,37, which are renumbered as claims 1-23.

3. Restriction/election: Applicants' above stated cancellation of claims, amendments to claims 1,2,29,32,34, and presentation of new claims 37 have limited the subject matter to elected invention of Group I, and species of Example 13 as recited in specification pages 97-98. The restriction/election is considered proper and has been made FINAL in earlier Office Action paper dated 10/22/03.

4. Rejections made under DP are also withdrawn because applicants have amended instant application as well as the co-pending U.S. Application Sr. NO. 09926712 filed 12/6/01. The instant application has a novelty in Lp (D) n bridge in which Xa is CH and Xb is N.

5. Applicants' above stated cancellation of claims 6,11,12,15-20,27-28,30-31,36, amendments to claims 1,2,29,32,34, and addition of new claim 37, together with their remarks and arguments are sufficient for withdrawal of the rejections made under 35 U.S.C. 112 paragraph second.

6. Rejections made under 35 U.S.C. 112 paragraph first are also now withdrawn because applicants have amended claim 29.

1. The closest prior art of record reference Kerwin et al (U.S.P. 5346907) teaches Amino Acid Analog CCK Antagonists with a core: " Heterocycle-NH-CO-N (R1)-CH (R2)-CO-NR3R4, wherein R3/R4 can form a piperidine ring". The ref.'907 differs by having piperidine-1-yl whereas the instant core has piperidine-4-yl. Additionally, the instant compounds have activity related to serine protease inhibition.

2. The ref. '907 does not indicate or suggest to arrive at instant compounds with a core: " Heterocycle-CO-NH-CH (Phenyl/Aryl)-CO-NH-Akylene-piperidin—4-yl-cyclopentane".

7. The other art(s) of record references WO 9912657/658 disclose compounds, which are Factor Xa inhibitors, and applicants have deleted the overlapping species of ref. WO 9925686 from instant claim 1.

8. The references either alone or in combination do not indicate or suggest arriving at instant compounds.

9. Therefore, the instant invention of Group I is deemed to be novel and patentably distinct.

10. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Art Unit: 1624

11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sudhaker B. Patel, D.Sc.Tech. whose telephone number is (571) 272-0671.


The examiner can normally be reached on 6:30 to 5:00 pm (Monday-Thursday).


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Mukund J. Shah can be reached on (571) 272 0674 or Sr. Examiner Mr. Richard Raymond at (571) 272 0673 or Mr. James Wilson at (571) 272-0661.

The assigned centralized fax number for the organization/USPTO for processing of this application or its proceedings is (703)-872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703 308 1235.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


Sudhaker B. Patel, D.Sc. Tech.
March 16, 2004.


MUKUND SHAH
SUPERVISORY PATENT
EXAMINER
ART UNIT 1624